CN106459067B - 用于治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物 - Google Patents

用于治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物 Download PDF

Info

Publication number
CN106459067B
CN106459067B CN201580031914.7A CN201580031914A CN106459067B CN 106459067 B CN106459067 B CN 106459067B CN 201580031914 A CN201580031914 A CN 201580031914A CN 106459067 B CN106459067 B CN 106459067B
Authority
CN
China
Prior art keywords
base
pyrazine
benzamide
fluoro
methylimidazole simultaneously
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580031914.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN106459067A (zh
Inventor
卢克·格林
伊曼纽尔·皮纳德
哈萨内·拉特尼
帕特里克·威廉松
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN106459067A publication Critical patent/CN106459067A/zh
Application granted granted Critical
Publication of CN106459067B publication Critical patent/CN106459067B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN201580031914.7A 2014-06-25 2015-06-22 用于治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物 Active CN106459067B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14173935 2014-06-25
EP14173935.9 2014-06-25
PCT/EP2015/063894 WO2015197503A1 (en) 2014-06-25 2015-06-22 Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy

Publications (2)

Publication Number Publication Date
CN106459067A CN106459067A (zh) 2017-02-22
CN106459067B true CN106459067B (zh) 2019-05-31

Family

ID=50980240

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580031914.7A Active CN106459067B (zh) 2014-06-25 2015-06-22 用于治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物

Country Status (10)

Country Link
US (1) US9975900B2 (https=)
EP (1) EP3160967B1 (https=)
JP (1) JP6675334B2 (https=)
KR (1) KR102565544B1 (https=)
CN (1) CN106459067B (https=)
BR (1) BR112016026951B1 (https=)
CA (1) CA2952895C (https=)
MX (1) MX375925B (https=)
RU (1) RU2725979C2 (https=)
WO (1) WO2015197503A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015024876A2 (en) 2013-08-19 2015-02-26 F. Hoffmann-La Roche Ag Screening method
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
KR102740831B1 (ko) 2017-11-14 2024-12-11 칠드런'즈 메디컬 센터 코포레이션 신규 이미다조피리미딘 화합물 및 그의 용도
EP3710007A4 (en) 2017-11-14 2021-12-15 Children's Medical Center Corporation USE OF IMIDAZOPYRIMIDINE TO MODULATE HUMAN IMMUNE RESPONSE
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
EP3814345B8 (en) 2018-06-27 2024-10-30 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
BR112020026637A2 (pt) 2018-06-27 2021-03-30 Reborna Biosciences, Inc. Agente profilático ou terapêutico para atrofia muscular espinhal
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
MA54755A (fr) * 2019-01-18 2021-11-24 Biogen Ma Inc Dérivés d'imidazo[1,2-a]pyridinyle servant d'inhibiteurs d'irak4
WO2020231977A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2021007378A1 (en) 2019-07-11 2021-01-14 Ptc Therapeutics, Inc. Compounds for use in treating huntington's disease
JP7736700B2 (ja) * 2020-02-28 2025-09-09 リミックス セラピューティクス インコーポレイテッド 複素環アミド及びスプライシングを調節するためのその使用
BR112022023025A2 (pt) * 2020-05-13 2023-03-28 Chdi Foundation Inc Moduladores de htt para tratar doença de huntington
US20250018046A1 (en) * 2021-07-07 2025-01-16 Biogen Ma Inc Compounds for targeting degradation of irak4 proteins
US12281116B2 (en) 2021-11-17 2025-04-22 Chdi Foundation, Inc. HTT modulators for treating Huntington's disease
CN118748995A (zh) * 2021-12-03 2024-10-08 亚根达医疗公司 5-嘧啶甲酰胺衍生物和其使用方法
AR132351A1 (es) 2023-04-13 2025-06-18 Syngenta Crop Protection Ag Derivados de imidazo[1,2-a]pirazina

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
WO2012080234A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2014012050A3 (en) * 2012-07-13 2014-03-20 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
WO2014078813A1 (en) * 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
WO2014209841A2 (en) * 2013-06-25 2014-12-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009013213A (es) * 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
KR102057351B1 (ko) * 2011-12-30 2019-12-18 피티씨 테라퓨틱스, 인크. 척수성 근위축증을 치료하기 위한 화합물
PE20150224A1 (es) * 2012-05-11 2015-03-08 Abbvie Inc Inhibidores del nampt
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005085252A1 (en) * 2004-03-04 2005-09-15 Biofocus Discovery Limited Imidazo ‘1,2-a’ pyrazine compounds which interact with protein kinases
WO2012080234A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
WO2014012050A3 (en) * 2012-07-13 2014-03-20 Indiana University Research & Technology Corporation Compounds for treatment of spinal muscular atrophy
WO2014078813A1 (en) * 2012-11-19 2014-05-22 Irm Llc Compounds and compositions for the treatment of parasitic diseases
WO2014209841A2 (en) * 2013-06-25 2014-12-31 F. Hoffmann-La Roche Ag Compounds for treating spinal muscular atrophy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The benzamide M344, a novel histone deacetylase inhibitor,significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells;Markus Riessland et al.;《Hum Genet》;20060525;第120卷;第101-110页 *

Also Published As

Publication number Publication date
EP3160967A1 (en) 2017-05-03
CA2952895C (en) 2023-09-26
EP3160967B1 (en) 2019-05-08
JP2017520570A (ja) 2017-07-27
RU2017102014A (ru) 2018-07-27
MX375925B (es) 2025-03-07
BR112016026951A2 (https=) 2017-08-15
CA2952895A1 (en) 2015-12-30
RU2725979C2 (ru) 2020-07-08
US20170197969A1 (en) 2017-07-13
KR102565544B1 (ko) 2023-08-10
CN106459067A (zh) 2017-02-22
MX2016015248A (es) 2017-02-23
RU2017102014A3 (https=) 2019-01-22
KR20170018076A (ko) 2017-02-15
JP6675334B2 (ja) 2020-04-01
US9975900B2 (en) 2018-05-22
WO2015197503A1 (en) 2015-12-30
BR112016026951B1 (pt) 2022-09-20

Similar Documents

Publication Publication Date Title
CN106459067B (zh) 用于治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物
CN105358151B (zh) 用于治疗脊髓性肌萎缩的化合物
CN106957317B (zh) 新型吡唑衍生物
CN101998959B (zh) 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
CN102271681B (zh) Cxcr7调节剂
CN115135650A (zh) 作为kras抑制剂的吡啶并嘧啶衍生物
JP7631235B2 (ja) 多発性硬化症のようなｃｎｓ障害を治療するためのｇｐｒ１７モジュレーターとしてのｎ‐（フェニル）‐インドール‐３‐スルホンアミド誘導体及び関連化合物
CN106795137B (zh) 氮杂环丁烷基氧基苯基吡咯烷化合物
TW201100400A (en) Piperazine compound capable of inhibiting prostaglandin d synthase
CN111410659A (zh) Pde9抑制剂及其用途
US9034864B2 (en) Azetidinyloxyphenylpyrrolidine compounds
CN118647613A (zh) 自噬诱导化合物及其用途，特别是用于中枢神经系统疾病
JP7110338B2 (ja) ムスカリンｍ１受容体陽性アロステリックモジュレーターである多環式アミド類
WO2013005798A1 (ja) 新規含窒素複素環誘導体
EP3551188A1 (en) Substituted quinazoline sulfonamides as thioredoxin interacting protein (txnip) inhibitors
TW202325305A (zh) ２－（芳基－２－基）嗎啉及其氘代衍生物、製備方法和應用
US20210322362A1 (en) Antiviral 1,3-di-oxo-indene compounds
US20260125357A1 (en) Lactate enhancing compounds and uses thereof
WO2024245974A1 (en) Oxopiperazine derivatives for the treatment of cancer
CN118791477A (zh) Aak1抑制剂及其用途
US20120016117A1 (en) Indazolepropionic acid amide compound
HK1230198B (zh) 用於治疗脊髓性肌萎缩的咪唑并[1，2-a]吡嗪-1基苯甲酰胺化合物
HK1230198A1 (en) Imidazo[1,2-a]pyrazin-1yl-benzamide compounds for treating spinal muscular atrophy

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1230198

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant